Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Sharlene Dong, Ankit J. Kansagra, Gurbakhash Kaur, Anna Barcellos, Andrew J. Belli, Laura L. Fernandes, Eric Hansen, Jacob Ambrose, Claire Bai, Christina M. Zettler, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2023-180263

Published: 2023

Journal Articles

Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)

Rebecca Bystrom, Laura L. Fernandes, Joseph Wynne, Dianne Pulte, Eric Hansen, Andrew J. Belli, Anna Barcellos, Christina M. Zettler, Jonathon Vallejo, Kelly Norsworthy, Angelo De Claro, Catherine Lerro, Marc R Theoret, Ching-Kun Wang, Donna Rivera

Blood (2023) 142 (Supplement 1): 5189.

https://doi.org/10.1182/blood-2023-189060

Published: 2023

Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 6536.

https://doi.org/10.1182/blood-2023-178727

Published: 2023

Journal Articles

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Blood (2023) 142 (Supplement 1): 6538.

https://doi.org/10.1182/blood-2023-180060

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)

Muhammad Saad Hamid, Claire Bai, Chelsea Perelgut, Helena Yelovich, Christina M. Zettler, Laura L. Fernandes, Andrew J. Belli, Eric Hansen, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2023-182064

Published: 2023

Journal Articles

Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials

Bindu Kanapuru, Laura L. Fernandes, Andrea Baines, Rachel Ershler, Vishal Bhatnagar, Elizabeth Pulte, Thomas Gwise, Marc R. Theoret, Richard Pazdur, Lola Fashoyin-Aje, Nicole Gormley

Blood (2023) 142 (3): 235–243.

https://doi.org/10.1182/blood.2022018657

Published: 2023

NARROW

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)

Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials

Email alerts

ASH Publications

American Society of Hematology

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)

Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only